Literature DB >> 20060400

A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene.

David J Araten1, Jose A Martinez-Climent, Mary Ann Perle, Eliana Holm, Leah Zamechek, Kimberly DiTata, Katie J Sanders.   

Abstract

It has been proposed that hypermutability is necessary to account for the high frequency of mutations in cancer. However, historically, the mutation rate (mu) has been difficult to measure directly, and increased cell turnover or selection could provide an alternative explanation. We recently developed an assay for mu using PIG-A as a sentinel gene and estimated that its average value is 10.6 x 10(-7) mutations per cell division in B-lymphoblastoid cell lines (BLCLs) from normal donors. Here we have measured mu in human malignancies and found that it was elevated in cell lines derived from T cell acute lymphoblastic leukemia, mantle cell lymphoma, follicular lymphoma in transformed phase, and 2 plasma cell neoplasms. In contrast, mu was much lower in a marginal zone lymphoma cell line and 5 other plasma cell neoplasms. The highest mu value that we measured, 3286 x 10(-7), is 2 orders of magnitude above the range we have observed in non-malignant human cells. We conclude that the type of genomic instability detected in this assay is a common but not universal feature of hematologic malignancies. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060400      PMCID: PMC2834866          DOI: 10.1016/j.mrfmmm.2009.11.012

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  34 in total

Review 1.  Rules for making human tumor cells.

Authors:  William C Hahn; Robert A Weinberg
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

Review 2.  In vivo somatic mutations in humans: measurement and analysis.

Authors:  R J Albertini; J A Nicklas; J P O'Neill; S H Robison
Journal:  Annu Rev Genet       Date:  1990       Impact factor: 16.830

Review 3.  Mutator phenotype may be required for multistage carcinogenesis.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

4.  Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes.

Authors:  R E Ware; C V Pickens; C M DeCastro; T A Howard
Journal:  Exp Hematol       Date:  2001-12       Impact factor: 3.084

5.  Metabolic cooperation between mouse embryonal carcinoma cells and their differentiated derivatives.

Authors:  J F Nicolas; H Jakob; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

6.  Mutation rate of normal and malignant human lymphocytes.

Authors:  R Seshadri; R J Kutlaca; K Trainor; C Matthews; A A Morley
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

Review 7.  Pitfalls and practice of Luria-Delbrück fluctuation analysis: a review.

Authors:  W S Kendal; P Frost
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

8.  Distinct mechanisms lead to HPRT gene mutations in leukemic cells.

Authors:  Ying-Wei Lin; Jonathan J Perkins; Zhenhua Zhang; Peter D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2004-04       Impact factor: 5.006

9.  Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones.

Authors:  D J Araten; M Bessler; S McKenzie; H Castro-Malaspina; B H Childs; F Boulad; A Karadimitris; R Notaro; L Luzzatto
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528

10.  FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow.

Authors:  P Keller; J L Payne; G Tremml; P A Greer; M Gaboli; P P Pandolfi; M Bessler
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

View more
  7 in total

1.  Both PIGA and PIGL mutations cause GPI-a deficient isolates in the Tk6 cell line.

Authors:  Janice A Nicklas; Elizabeth W Carter; Richard J Albertini
Journal:  Environ Mol Mutagen       Date:  2015-05-13       Impact factor: 3.216

2.  The rate of spontaneous mutations in human myeloid cells.

Authors:  David J Araten; Ondrej Krejci; Kimberly Ditata; Mark Wunderlich; Katie J Sanders; Leah Zamechek; James C Mulloy
Journal:  Mutat Res       Date:  2013-06-06       Impact factor: 2.433

Review 3.  Do mutator mutations fuel tumorigenesis?

Authors:  Edward J Fox; Marc J Prindle; Lawrence A Loeb
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

4.  Leukemic blasts with the paroxysmal nocturnal hemoglobinuria phenotype in children with acute lymphoblastic leukemia.

Authors:  David J Araten; Katie J Sanders; Dan Anscher; Leah Zamechek; Stephen P Hunger; Sherif Ibrahim
Journal:  Am J Pathol       Date:  2012-08-30       Impact factor: 4.307

5.  PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Authors:  Emmanuel K Teye; Abigail Sido; Ping Xin; Niklas K Finnberg; Prashanth Gokare; Yuka I Kawasawa; Anna C Salzberg; Sara Shimko; Michael Bayerl; W Christopher Ehmann; David F Claxton; Witold B Rybka; Joseph J Drabick; Hong-Gang Wang; Thomas Abraham; Wafik S El-Deiry; Robert A Brodsky; Raymond J Hohl; Jeffrey J Pu
Journal:  Oncotarget       Date:  2017-05-02

6.  Application of counter-selectable marker PIGA in engineering designer deletion cell lines and characterization of CRISPR deletion efficiency.

Authors:  Donghui Li; Xiaoji Sun; Fangzhou Yu; Mary Ann Perle; David Araten; Jef D Boeke
Journal:  Nucleic Acids Res       Date:  2021-03-18       Impact factor: 16.971

7.  PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression.

Authors:  Emmanuel K Teye; Shasha Lu; Fangyuan Chen; Wenrui Yang; Thomas Abraham; Douglas B Stairs; Hong-Gang Wang; Gregory S Yochum; Robert A Brodsky; Jeffrey J Pu
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.